AFINITOR vs DANZITEN

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 4, 2026·How we rate

Possible drug interaction. AFINITOR and DANZITEN are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	AFINITOR	DANZITEN
Rating	70/100	72/100
Pharmacy pays	~$219.28 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	NILOTINIB TARTRATE
Manufacturer	Novartis	Azurity
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

afinitor danziten

Rating

70/100

72/100

Pharmacy pays

~$219.28 /30

—

Type

Active ingredient

EVEROLIMUS

NILOTINIB TARTRATE

Manufacturer

Novartis

Azurity

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia, Gastrointestinal Stromal Tumors

Frequently asked questions

Which is better-rated, Afinitor or Danziten?

By our independent rating, Danziten scores higher — 3.6 vs 3.5 out of 5 for Afinitor. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Afinitor and Danziten?

Afinitor contains Everolimus, while Danziten contains Nilotinib Tartrate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.